Tango Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Rhea-AI Summary

Tango Therapeutics (NASDAQ: TNGX) announced that Malte Peters, M.D., President and CEO, will appear in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 2:00 PM EST. The event will be webcast live and a replay will be archived on the company website for 90 days.

Key Figures

Summit date: February 12, 2026 Event time: 2:00 PM EST Webcast archive period: 90 days

3 metrics

Summit date February 12, 2026 Date of Guggenheim Emerging Outlook: Biotech fireside chat

Event time 2:00 PM EST Scheduled time for the fireside chat

Webcast archive period 90 days Replay available on company website after presentation

Market Reality Check

Price: $12.55 Vol: Volume 1,915,564 is at 0....

low vol

$12.55 Last Close

Volume Volume 1,915,564 is at 0.6x the 20-day average. low

Technical Trading above 200-day MA of 6.81, with price at 11.94.

Peers on Argus

Biotech peers show mixed moves: some up (e.g., IMTX +5.6%, SANA +5.03%) and some...

Biotech peers show mixed moves: some up (e.g., IMTX +5.6%, SANA +5.03%) and some down (AVXL -2.16%), while scanner data does not flag a coordinated sector momentum move.

Historical Context

5 past events · Latest: Jan 08 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 08	CEO transition	Neutral	-6.2%	Founding CEO retires; Malte Peters becomes President and CEO.
Jan 05	Board appointment	Positive	-0.2%	Experienced finance executive Sung Lee joins the board.
Dec 17	Conference participation	Neutral	-2.0%	Corporate presentation at J.P. Morgan Healthcare Conference announced.
Nov 26	Conference participation	Neutral	+1.8%	Piper Sandler healthcare conference fireside chat participation disclosed.
Nov 12	Conference participation	Neutral	-8.5%	Jefferies Global Healthcare Conference fireside chat participation announced.

Pattern Detected

Recent leadership and conference announcements often saw negative next-day moves, with only one of the last five events showing a positive 24-hour reaction.

Recent Company History

Over the last few months, Tango reported leadership changes, board strengthening, and multiple healthcare conference appearances. The CEO transition on Jan 8, 2026 coincided with a -6.23% move, while prior conference participations around Jefferies, Piper Sandler, and J.P. Morgan produced mixed single-day reactions ranging from -8.47% to +1.8%. Today’s announcement of participation in another investor-focused biotech summit continues this pattern of non-clinical, investor-relations oriented updates.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-11-21

An active Form S-3 resale shelf dated Nov 21, 2025 covers up to 1,732,101 already-issued shares from an October 2025 private placement at $8.66 per share. The company will receive no cash from resales under this prospectus, as proceeds were realized when the private placement closed.

Market Pulse Summary

This announcement highlights Tango’s participation in a Guggenheim biotech summit, with a webcast at...

Analysis

This announcement highlights Tango’s participation in a Guggenheim biotech summit, with a webcast at 2:00 PM EST on February 12, 2026 and a replay available for 90 days. It continues a pattern of active conference engagement seen in recent months. In context with prior filings detailing cash levels, ATM capacity, and a resale shelf, investors may focus on any incremental commentary from management on pipeline progress and capital planning during the event.

AI-generated analysis. Not financial advice.

BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Malte Peters, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 2:00 PM EST.

The live webcast will be available under the "Events & Presentations" tab on the “Investors” page of the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com.

Investors and Media:

Elizabeth Hickin
IR@tangotx.com
media@tangotx.com

FAQ

When will Tango Therapeutics (TNGX) present at the Guggenheim Emerging Outlook: Biotech Summit 2026?

Tango Therapeutics will present on Thursday, February 12, 2026 at 2:00 PM EST. According to Tango Therapeutics, Malte Peters, M.D., President and CEO, is scheduled for a fireside chat at that time.

How can investors watch the Tango Therapeutics (TNGX) fireside chat on February 12, 2026?

Investors can watch via a live webcast available on the company’s investor site under Events & Presentations. According to Tango Therapeutics, the webcast will be accessible on the Investors page the day of the event.

Will a replay of the Tango Therapeutics (TNGX) Guggenheim presentation be available after the event?

Yes, a replay will be archived for 90 days on the company website. According to Tango Therapeutics, the replay will be posted after the presentation and remain available for three months.

Who from Tango Therapeutics (TNGX) will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026?

Malte Peters, M.D., President and Chief Executive Officer, will participate in a fireside chat. According to Tango Therapeutics, he is scheduled to speak on February 12, 2026 at 2:00 PM EST.